



innovation for health & wellness

“trace & catch”

## Instruction for Use

Antibody to Omalizumab (Xolair®)

# SHIKARI® S-ATO

Enzyme immunoassay for the qualitative determination (screening) of Omalizumab (Xolair®) in serum and plasma

REF TR-AAT0v1



12 x8



2-8 C

Revision # 1.1 December 2016



Matriks Biotek Laboratories  
[www.matriksbiotek.com](http://www.matriksbiotek.com)

<b>Contents</b>	<b>Page</b>
Intend to use.....	3
Summary and Explanation.....	3
Test Principle .....	3
Warnings and Precautions .....	4
Storage and Stability.....	5
Specimen Collection and Storage.....	5
Materials Supplied.....	6
Materials Required but not Supplied .....	7
Procedure Notes.....	7
Preparation of Component .....	8
Test Procedure.....	9
Interpretation of Results.....	10
References.....	11

	<b>SHIKARI® S-ATO</b>
	Omalizumab (Xolair® ) antibodies qualitative analyse
Required Volume (µl)	10
Total Time (min)	140
Sample	Serum, plazma
Sample Number	96
Detection Limit (ng/mL)	+/-
Spike Recovery (%)	-
Shelf Life (year)	1

## Intended Use

The Matriks Biotek Antibody to omalizumab (Xolair®) Enzyme-Linked-ImmunoSorbent-Assay (ELISA) Kit is intended for the qualitative determination of antibodies to omalizumab (Xolair®) in serum and plasma. It is for professional use only.

## Summary and Explanation

According to the prospectus; Xolair is approved by the U.S. Food and Drug Administration (FDA) for use in adults and adolescents 12 years of age and older, who have moderate to severe persistent asthma and a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. Xolair is not indicated for acute bronchospasm or status asthmaticus. Xolair is also approved for chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H1 antihistamine treatment. It is not indicated for other allergic conditions or other forms of urticaria. Because of the risk of anaphylaxis, healthcare providers administering Xolair should observe patients closely for an appropriate period of time and be prepared to manage anaphylaxis that can be life-threatening.

On September 26, 2014, the U.S. FDA released a drug safety alert entitled: FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug Xolair (omalizumab) than in those who were not treated with Xolair. As a result, FDA has added information about these potential risks to the drug label. Additionally, reviewers found no difference in the rates of cancer between those patients being treated with Xolair and those who were not being treated with Xolair. However, due to limitations in the 5-year study, FDA cannot rule out a potential risk of cancer with Xolair, so this information was added to the Warnings and Precautions section of the drug label.

## Test Principle

The Matriks Biotek Antibody to omalizumab (Xolair®) ELISA is a sandwich assay for the determination of antibodies against omalizumab in serum and plasma samples. During the first incubation period, antibodies to omalizumab (ATO) in patient serum/ plasma samples are captured by the drug omalizumab (Xolair®) coated on the wall of the microtiter wells. After washing away the unbound components from samples, a peroxidase-labelled specific conjugate is added to each well and then incubated.

After a second washing step, the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The intensity of the reaction color is directly proportional to the concentration of ATO in sample.

## Warnings and Precautions

1. For professional use only.
2. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
3. In case of severe damage of the kit package please contact Matriksbiotek or your supplier in written form, latest one week after receiving the kit. Do not use damaged components in test runs, but keep safe for complaint related issues.
4. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
5. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
6. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
7. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
8. Avoid contact with Stop solution. It may cause skin irritations and burns.
9. Some reagents contain sodium azide ( $\text{NaN}_3$ ) as preservatives. In case of contact with eyes or skin, flush immediately with water.  $\text{NaN}_3$  may react with lead and copper plumbing to form explosive metal azides. When disposing reagents, flush with large volume of water to avoid azide build-up.
10. All reagents of this test kit containing human serum or plasma have been tested and were found negative for HIV I/II, HBsAg and HCV by FDA approved procedures. However, a presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.

## Storage and Stability

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The strips of microtiter plate is stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

## Specimen Collection and Storage

### Serum, Plasma (EDTA, Heparin)\*

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

Storage:	2-8°C	-20°C	Keep away from heat or direct sun light
Stability:	7 d	6 mon	Avoid repeated freeze-thaw cycles

\*. Omalizumab (Xolair®) infusion camouflages/masks the presence of antibody to Omalizumab in serum/plasma samples. Therefore, blood sampling time is critical for detection of Omalizumab. Matriks Biotek Laboratories propose to obtain blood sample just before the infusion of Omalizumab (Xolair®) or at least 2 weeks after the infusion of Omalizumab (Xolair®).

## Materials Supplied

1 x 12 x 8	MTP	<b>Microtiter Plate</b> Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with omalizumab.
1 x 0.25 mL	RCTV CNTR	<b>Reactive Control</b> Ready-to-use. Contains omalizumab -reactive reagent, human serum, stabilizers and <0.1% NaN <sub>3</sub>
1 x 0.5 mL	NEG CNTR	<b>Negative Control</b> Ready-to-use. Contains human serum, stabilizers and <0.1% NaN <sub>3</sub>
1 x 12 mL	ASSAY BUF	<b>Assay Buffer</b> Blue colored. Ready to use. Contains proteins, RF blockers and <0.1% NaN <sub>3</sub>
1 x 12 mL	POD CONJ	<b>Peroxidase Conjugate</b> Red colored. Ready to use. Contains peroxidase (POD) conjugate, RF blockers, stabilizer and preservatives.
1 x 12 mL	TMB SUBS	<b>TMB Substrate Solution</b> Ready to use. Contains TMB
1 x 12 mL	TMB STOP	<b>TMB Stop Solution</b> Ready to use. 1N HCl.
1 x 50 mL	WASHBUF CONC	<b>Wash Buffer, Concentrate (20x)</b> Contains Buffer with Tween 20.
2 x 1	ADH FILM	<b>Adhesive Film</b> For covering of Microtiter Plate during incubation.

## Materials Required but not Supplied

1. Micropipettes (< 3% CV) and tips to deliver 5-1000  $\mu\text{L}$ .
2. Bidistilled or deionised water
3. Calibrated measures.
4. Absorbent paper and timer.
5. Standard laboratory glass or plastic vials, cups, etc.
6. Wash bottle, automated or semi-automated microtiter plate washing system
7. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength 620-690 nm is optional).

## Procedure Notes

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pretreatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared ready at the appropriate time. Allow all reagents and specimens to reach room temperature (18-25  $^{\circ}\text{C}$ ) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange caps. Always cap not used vials. Do not reuse wells/tubes or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells/tubes. Do not open the pouch until it reaches room temperature. Unused wells/tubes should be returned immediately to the resealed pouch including the desiccant.

## Preparation of Component

Dilute/ dissolve	Component	with	Diluent	Relation	Remarks	Storage	Stability
10 mL	Wash Buffer*	Up to 200 mL	Bidist. water	1:20	Warm up at 37°C to dissolve crystals. Mix vigorously.	2-8 °C	3 w

\*. Prepare Wash Buffer before starting assay procedure.



## Test Procedure

1	Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used.
2	<p><b>QUALITATIVE ELISA TEST FORMAT</b></p> <p>Pipette 10 µL of ready-to use Cut-Off Serum, Reactive Control, and Samples into the respective wells of microtiter plate.</p> <p><u>Wells</u></p> <p>A1:                      Negative Control            B1:                      Negative Control            C1:                      Reactive Control            D1 and on.:            Sample (Serum/Plasma)</p>
3	Cover the plate with adhesive film. Briefly mix contents by gently shaking the plate. Incubate 60 min at room temperature (18-25°C).
4	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
5	Pipette 100 µL of ready-to use Peroxidase Conjugate into each well.
6	Cover the plate with adhesive film. Incubate 60 min at room temperature (18- 25°C).
7	Remove adhesive film. Discard incubation solution. Wash plate 3 times each with 300 µL of diluted Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel.
8	Pipette 100 µL of TMB Substrate Solution into each well.
9	Incubate 20 min (without adhesive foil.) at room temperature (18-25°C) in the dark.
10	Stop the substrate reaction by adding 100 µL of Stop Solution into each well. Briefly mix contents by gently shaking the plate. Color changes from blue to yellow
11	Measure optical density with a photometer at 450/650 nm within 30 min after pipetting of the Stop Solution.

## Interpretation Of Results

For the run to be valid, the OD<sub>450/650</sub> nm of Positive Control should be  $\geq 1.00$  and the OD<sub>450/650</sub> nm of each Negative Control should be  $< 0.200$ . If not, improper technique or reagent deterioration may be suspected and the run should be repeated.

The results are evaluated by a cut-off value which is estimated by multiplying the mean OD<sub>450/650</sub> nm of the negative controls by 3.

I.e.;

If "Sample OD<sub>450/650</sub>/the mean OD<sub>450/650</sub> of Negative Controls" is  $\geq 3$ , the sample is

**POSITIVE**

If "Sample OD<sub>450/650</sub>/the mean OD<sub>450/650</sub> of Negative Controls" is  $< 3$ , the sample is  
**NEGATIVE**

## REFERENCES

1. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol.* 2015 Jan;135(1):67-75.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention - revised 2014. Accessed March 31, 2015.
3. Xolair® [package insert]. South San Francisco, CA: Genentech, Inc., September 2014.
4. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with antiimmunoglobulin E antibody (omalizumab). *Pediatrics.* 2001;108(2):E36.
5. Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. *Pediatrics.* 2002;110(5):e55.
6. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the antiIgE antibody, omalizumab, in children with allergic asthma. *Ann Allergy Asthma Immunol.* 2003;91(2):182-8.
7. National Institute for Health and Care Excellence (NICE). Omalizumab for treating severe persistent allergic asthma (review of technology appraisal guidance 133 and 201). London (UK): National Institute for Health and Care Excellence (NICE); 2013 Apr. 64 p. (Technology appraisal guidance; no. 278).
8. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. *J Allergy Clin Immunol.* 2009;124(6):1210-6.
9. Xolair Solution for Injection. Omalizumab. Annex I. Summary of Product Characteristics. Nuremberg, Germany: Novartis; October 25, 2010.
10. Casale TB, Condemi J, LaForce C, et al. Omalizumab Seasonal Allergic Rhinitis Trial Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. *JAMA.* 2001;286(23):2956-67.
11. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. *Allergy Asthma Proc.* 2003;24(5):323-9.
12. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. *Allergy.* 2004;59(9):973-979.
13. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. *J Allergy Clin Immunol.* 2002;109(2):274-80.
14. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. *Clin and Exp Allergy.* 2009;39(2):271-9.
15. Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. *J Allergy Clin Immunol.* 2006;117(1):134-40.

16. Corren J, Diaz-Sanchez D, Saxon A, et al. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. *Ann Allergy Asthma Immunol.* 2004;93(3):243-8.
17. Corren J, Shapiro G, Reimann J, et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. *J Allergy Clin Immunol.* 2008;121(2):506-11.
18. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. *Ann Allergy Asthma Immunol.* 2003;91(2):160-7.